Skip to main content

Zykadia Side Effects

Generic name: ceritinib

Medically reviewed by Philip Thornton, DipPharm. Last updated on Apr 28, 2023.

Note: This document contains side effect information about ceritinib. Some dosage forms listed on this page may not apply to the brand name Zykadia.

Applies to ceritinib: oral tablet.

Serious side effects of Zykadia

Along with its needed effects, ceritinib (the active ingredient contained in Zykadia) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking ceritinib:

More common

Less common

Other side effects of Zykadia

Some side effects of ceritinib may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common

Incidence not known

For Healthcare Professionals

Applies to ceritinib: oral capsule, oral tablet.

General

The most common side effect resulting in dose reductions or interruptions were increased ALT (29%), nausea (20%), increased AST (16%), diarrhea (16%), and vomiting (16%).

The most common side effects leading to discontinuation were pneumonia, interstitial lung disease/pneumonitis, and decreased appetite.[Ref]

Gastrointestinal

Very common (10% or more): Diarrhea (86%), nausea (80%), vomiting (60%), abdominal pain (54%), constipation (29%), esophageal disorder (16%)

Rare (less than 0.1%): GI hemorrhage[Ref]

Hematologic

Very Common (10% or more): Hemoglobin decreased (84%), phosphate decreased (36%)[Ref]

Hepatic

Very Common (10% or more): ALT increased (80%), AST increased (75%), bilirubin increased (15%)[Ref]

Renal

Very Common (10% or more): Creatinine increased (58%), phosphate decreased (36%)[Ref]

Metabolic

Very common (10% or more): Decreased appetite (34%), glucose increased (49%), lipase increased (28%)[Ref]

Dermatologic

Very common (10% or more): Rash (16%)[Ref]

Respiratory

Common (1% to 10%): Interstitial lung disease/pneumonitis

Rare (0.01% than 0.1%): Respiratory failure, pneumothorax, pulmonary tuberculosis[Ref]

Nervous system

Very common (10% or more): Neuropathy (17%)[Ref]

Ocular

Common (1% to 10%): Vision disorder[Ref]

Cardiovascular

Common (1% to 10%): Prolonged QT, bradycardia

Rare (less than 0.1%): Cardiac tamponade[Ref]

Other

Very common (10% or more): Fatigue (52%)

Uncommon (0.1% to 1%): General physical health deterioration[Ref]

Immunologic

Rare (less than 0.1%): Sepsis[Ref]

Frequently asked questions

References

1. Product Information. Zykadia (ceritinib). Novartis Pharmaceuticals. 2014.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.